Storys aus Hattersheim, Germany

Filtern
  • 03.07.2020 – 08:30

    CSL Behring

    IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing

    Hattersheim, Germany (ots/PRNewswire) - European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® ...